Klinsman Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 04-12-2024
- Paid Up Capital ₹ 0.10 M
as on 04-12-2024
- Company Age 4 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2022)
- Profit 161.79%
(FY 2022)
- Ebitda 163.25%
(FY 2022)
- Net Worth 5130.59%
(FY 2022)
- Total Assets 4479.35%
(FY 2022)
About Klinsman Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Shashi Sharma and Shweta Sharma serve as directors at the Company.
- CIN/LLPIN
U24299MH2020PTC349345
- Company No.
349345
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Nov 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Klinsman Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shweta Sharma  | Director | 03-Nov-2020 | Current |
| Shashi Sharma | Director | 03-Nov-2020 | Current |
Financial Performance of Klinsman Pharma.
Klinsman Pharma Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 161.79% increase in profit. The company's net worth Soared by an impressive increase of 5130.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Klinsman Pharma?
In 2022, Klinsman Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Sbs Healthcare Services Private LimitedActive 7 years 10 months
Shashi Sharma and Shweta Sharma are mutual person
- Sbs Super Speciality Hospital Private LimitedActive 4 years 18 days
Shashi Sharma is a mutual person
- Sbs Divine Super Speciality Hospital Private LimitedActive 6 months 29 days
Shashi Sharma and Shweta Sharma are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Klinsman Pharma?
Klinsman Pharma has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Klinsman Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Klinsman Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.